These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20089977)

  • 1. Clostridium difficile--beyond antibiotics.
    Kyne L
    N Engl J Med; 2010 Jan; 362(3):264-5. PubMed ID: 20089977
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with monoclonal antibodies against Clostridium difficile toxins.
    Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM
    N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with monoclonal antibodies against Clostridium difficile toxins.
    Safdar A
    N Engl J Med; 2010 Apr; 362(15):1444-5; author reply 1445-6. PubMed ID: 20397289
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
    Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
    Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
    Babcock GJ; Broering TJ; Hernandez HJ; Mandell RB; Donahue K; Boatright N; Stack AM; Lowy I; Graziano R; Molrine D; Ambrosino DM; Thomas WD
    Infect Immun; 2006 Nov; 74(11):6339-47. PubMed ID: 16966409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection.
    Gens KD; Elshaboury RH; Holt JS
    J Pharm Pract; 2013 Oct; 26(5):498-505. PubMed ID: 23966282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
    Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
    Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with monoclonal antibodies against Clostridium difficile toxins.
    Dawson AE; Shumak SL; Redelmeier DA
    N Engl J Med; 2010 Apr; 362(15):1445; author reply 1445-6. PubMed ID: 20397290
    [No Abstract]   [Full Text] [Related]  

  • 10. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
    Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridium difficile antibodies: a patent evaluation (WO2013028810).
    Lo Vecchio A; Della Ventura B; Nicastro E
    Expert Opin Ther Pat; 2013 Dec; 23(12):1635-40. PubMed ID: 23978053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
    Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
    Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
    Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
    Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model.
    Cohen OR; Steele JA; Zhang Q; Schmidt DJ; Wang Y; Hamel PE; Beamer G; Xu B; Tzipori S
    PLoS One; 2014; 9(10):e111075. PubMed ID: 25347821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrepancies in testing recommendations for Clostridium difficile infection: updated review favors amplification test systems.
    Chapin K
    Expert Rev Mol Diagn; 2012 Apr; 12(3):223-6. PubMed ID: 22468811
    [No Abstract]   [Full Text] [Related]  

  • 16. Clostridium difficile lacks detectable superantigen activity.
    Wanahita A; Davis B; Hamill RJ; Goldsmith EA; Rodgers JR; Cook RG; Lamphear JG; Musher DM
    FEMS Immunol Med Microbiol; 2006 Jul; 47(2):275-7. PubMed ID: 16831215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent Clostridium difficile infection: an immunodeficiency state?
    Pardi DS
    Clin Gastroenterol Hepatol; 2007 Jun; 5(6):672-3. PubMed ID: 17544993
    [No Abstract]   [Full Text] [Related]  

  • 18. A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.
    Schmidt DJ; Beamer G; Tremblay JM; Steele JA; Kim HB; Wang Y; Debatis M; Sun X; Kashentseva EA; Dmitriev IP; Curiel DT; Shoemaker CB; Tzipori S
    Clin Vaccine Immunol; 2016 Sep; 23(9):774-84. PubMed ID: 27413067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridial toxins: sensing a target in a hostile gut environment.
    Oezguen N; Power TD; Urvil P; Feng H; Pothoulakis C; Stamler JS; Braun W; Savidge TC
    Gut Microbes; 2012; 3(1):35-41. PubMed ID: 22356854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of whey protein concentrate derived from the milk of cows immunized against Clostridium difficile.
    Young KW; Munro IC; Taylor SL; Veldkamp P; van Dissel JT
    Regul Toxicol Pharmacol; 2007 Apr; 47(3):317-26. PubMed ID: 17293018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.